The object of this randomized, placebo controlled, double blind study is to test the hypothesis that the addition of Buspirone would improve psychopathology in subjects with Schizophrenia treated with Typical Antipsychotics. 50 patients with ages between 18-65 years who have no other medical or psychiatric conditions with chronic DSMIV-TR diagnosed Schizophrenia will receive Typical Antipsychotics combined with either placebo (N=25) or 30 mg/day of Buspirone (N=25) for 6 weeks. Efficacy will be defined as the change from baseline to endpoint in score on the Possitive and Negative Syndrom Scale(PANSS). Side effects will be also evaluated using checklist and Extrapyramidal Symptom Rating Scale. PANSS, SAS, GAF, MMSE Scales and side effects will be evaluated at baseline,2,4 and 6 weeks.